.png){kind=icon}
.png){kind=icon}
Return
Inflammation-Responsive Nanocolloidal Hydrogel Enables On-Demand Gene Activation for Osteoarthritis Therapy
.png){kind=icon}
PRE
AI
Y
Y
Y
K
X
Q
G
B
DOI：10.1002/adhm.71557.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Synovitis-driven inflammation and oxidative stress are key drivers of osteoarthritis (OA) progression. As a master regulator of antioxidant and anti-inflammatory defenses, nuclear factor erythroid 2-related factor 2 (Nrf2) represents a promising therapeutic target. However, current strategies for Nrf2 activation remain limited in achieving durable synovial gene expression and pathology-adaptive release. Here, we developed an injectable inflammation-responsive nanocolloidal hydrogel enabling sustained and on-demand Nrf2 activation within OA joints. The hydrogel was fabricated by crosslinking polyvinyl alcohol (PVA) with phenylboronic acid (PBA)-functionalized nanoparticles encapsulating Nrf2 plasmids. Dynamic boronate ester linkages between PBA and PVA enabled rapid in situ gelation after intra-articular injection. In the ROS-enriched inflammatory microenvironment of OA, cleavage of boronate ester bonds triggered the release of Nrf2 plasmid-loaded nanoparticles. The released nanoparticles were efficiently internalized by fibroblast-like synoviocytes (FLSs) and promoted Nrf2 expression, thereby suppressing oxidative stress and inflammatory responses. In ACLT-induced OA mice, the hydrogel markedly alleviated synovial inflammation, preserved cartilage matrix, and reduced the OARSI score by approximately 70%. These findings highlight its potential as a promising strategy for inflammation-adaptive gene regulation in OA therapy.
Keywords:
inflammation-responsive hydrogel
Nrf2 plasmids
on-demand gene activation
osteoarthritis therapy
Journal
IF:
9.6
Papers:
7.5K
Citations:
4.4W
Organization
Cited Papers